Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis
- 21 February 2004
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 12 (7) , 531-536
- https://doi.org/10.1007/s00520-004-0597-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental StudiesPharmacological Reviews, 2001
- Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic DiseaseAnnals of Internal Medicine, 2001
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Low-molecular-weight heparin in the management of Trousseau's syndrome.1997
- Venous thromboembolism and cancer A two-way clinical associationFrontiers in Bioscience-Landmark, 1997
- HYPERCOAGULABILITY IN CANCERHematology/Oncology Clinics of North America, 1996
- Once-daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein ThrombosisThrombosis and Haemostasis, 1996
- Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and SafetyChest, 1995
- Comparison of Once-Daily Subcutaneous Fragmin® with Continuous Intravenous Unfractionated Heparin in the Treatment of Deep Vein ThrombosisThrombosis and Haemostasis, 1994
- A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.1991